Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
- FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population
- Oral presentation on preclinical data for FHD-909 in combination with chemotherapy, pembrolizumab and KRAS inhibitors, in SMARCA4 mutant cancers
- Poster presentations on preclinical data for Selective CBP degrader in combination with chemotherapy and targeted agents and for Selective EP300 degrader in hematological malignancies
CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that new preclinical combination data for FHD-909, a potential first-in-class selective SMARCA2 inhibitor will be presented as an oral presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting being held April 25-30, 2025, in Chicago, Illinois. Poster presentations on the Phase 1 trial design for FHD-909 and on preclinical data for the Selective CBP program and the Selective EP300 degrader program will also be presented.
'We are excited to share new preclinical data at this year's AACR conference further strengthening the promise of our differentiated programs,' said Adrian Gottschalk, President, and Chief Executive Officer of Foghorn. 'Importantly, enrollment and dose escalation are on track in the ongoing Phase 1 trial evaluating FHD-909, a first-in-class oral selective SMARCA2 inhibitor, in SMARCA4 mutated cancers with initial focus in NSCLC. New preclinical data on expansion opportunities for FHD-909 in combination with chemotherapy, pembrolizumab and KRAS inhibitors, in SMARCA4 mutant cancers will be featured in an oral presentation. We look forward to continued progress on our FHD-909 program in collaboration with Lilly.'
Mr. Gottschalk added, 'Our Selective CBP degrader and Selective EP300 degrader programs have shown highly selective and robust anti-tumor activities, and two poster presentations will highlight preclinical data supporting their advancement towards the clinic. Our pipeline programs continue to show unmatched selectivity for challenging targets, and we are focused on strong execution across our portfolio.'
Presentation Details
FHD-909
Oral Presentation Title: LY4050784, a selective inhibitor of SMARCA2, demonstrates synergistic activity in combinations with pembrolizumab or KRAS inhibitorsMini Symposium: Experimental and Molecular Therapeutics – Continuum of Innovation: Biological Therapeutic AgentsSession Date/Time: Monday, April 28, 2:30 p.m. – 4:30 p.m. CDTPresenter: Nathan Brooks, Pharmacology Team Leader, Oncology, Eli Lilly And Company
Poster Presentation Title: A First-in-human Phase 1 Study of LY4050784, an Oral, Potent, and Selective SMARCA2 Inhibitor, in Patients with Advanced Solid Tumors with SMARCA4 Alterations (Trial in Progress)Session: Phase I Clinical Trials in Progress 1Poster Number: 51/4Session Date/Time: Monday, April 28, 2:00 p.m. – 5:00 p.m. CDTPresenter: Timothy A. Yap, MBBS, PhD, FRCP, Professor of Investigational Cancer Therapeutics, MD Anderson Cancer Center
Selective CBP Degrader
Poster Presentation Title: Establishing rational combination strategies with selective CBP degraders in solid tumor indicationsSession: Experimental and Molecular Therapeutics – Degraders and Glues 2Poster Number: 18 / 3Session Date/Time: Monday, April 28, 9:00 a.m. – 12:00 p.m. CDTPresenter: Molly M. Wilson, Scientist, Biology, Foghorn Therapeutics
Selective EP300 Degrader
Poster Title: Anti-cancer activity of potent and selective EP300 degradation in hematological malignanciesSession: Clinical Research – Molecular Genetics and Epigenetics of TumorsPoster Number: 34 / 17Session Date/Time: Wednesday, April 30, 9:00 a.m. – 12:00 p.m. CDTPresenter: Claudia Dominici, Scientist, Biology, Foghorn Therapeutics
The presentation and the posters will be accessible under the Science section of the Company's website after the conference.
About FHD-909
FHD-909 (LY4050784) is a potent, first-in-class, allosteric and orally available small molecule that selectively inhibits the ATPase activity of SMARCA2 (BRM) over its closely related paralog SMARCA4 (BRG1), two proteins that are the catalytic engines across all forms of the BAF complex, one of the key regulators of the chromatin regulatory system. In preclinical studies, tumors with mutations in SMARCA4 rely on SMARCA2 for BAF function. FHD-909 has shown significant anti-tumor activity across multiple SMARCA4 mutant lung tumor models.
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn.
Forward-Looking Statements
This press release contains 'forward-looking statements.' Forward-looking statements include statements regarding the Company's clinical trials, including the ongoing Phase 1 trial evaluating FHD-909, a first-in-class oral selective SMARCA2 inhibitor, in SMARCA4 mutated cancers, product candidates and research efforts and other statements identified by words such as 'could,' 'may,' 'might,' 'will,' 'likely,' 'anticipates,' 'intends,' 'plans,' 'seeks,' 'believes,' 'estimates,' 'expects,' 'continues,' 'projects' and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made.
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc. khellsvik@foghorntx.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
37 minutes ago
- Business Wire
University of Phoenix and Jobs for the Future Partner to Help Employers Harness Effective Upskilling and Reskilling at Scale
PHOENIX--(BUSINESS WIRE)-- University of Phoenix and Jobs for the Future (JFF), a national nonprofit driving transformation in the U.S. workforce and education systems, announce a new project in their continued partnership; to pilot and evaluate an AI-powered skills analysis and upskilling business outcomes strategy that accurately captures and understands employee skills, tech integration and employer adoption of skills pathways for their workforce. The collaboration comes at a pivotal moment. According to the World Economic Forum, 39% of core job skills are expected to change by 2030. Yet many organizations still do not center understanding of workforce skills and development opportunities in their business strategy; the 2025 Career Optimism Index® study found that while 86% of workers are actively seeking skill development opportunities, employer investment in reskilling and upskilling has declined by 13 and 10 points, respectively, since 2022. 'As AI reshapes the workforce, the companies that thrive won't necessarily be those with the best technology, but those with the most adaptable people,' said Raghu Krishnaiah, Chief Operating Officer at University of Phoenix. 'We seek to close the gap between aspiration and action by effective implementation of a business strategy that centers the skills needed for the success of the organization and embeds learning and career pathways for employees based on their skillsets.' The project aims to uncover how skills-focused, AI-enabled tools can drive better outcomes in employee development, retention, and mobility—while also addressing critical issues like algorithmic transparency and data accountability. With support from University of Phoenix, JFF will conduct discovery and analysis, including exploration of strategies that create impact through skills validation and upskilling; and then through piloting, testing and market experience with employers that feature diversely skilled workforce populations. The initiative will conduct analysis and testing with the University's technology affiliate, Skillmore™, an AI skills intelligence platform, in collaboration with employers. 'During this critical adoption phase of AI technology platforms by companies, JFF is deeply committed to a thorough examination of these platforms to better understand employer and employee impact, as well as to support responsible AI design,' states Alison Lands, Vice President, Employer & Workforce Solutions, JFF. 'This initiative allows us to co-design solutions that are innovative and responsive to the needs of a broad and evolving workforce.' The shared project highlights mission alignment between the two organizations in supporting working adult learners: JFF has established a North Star that by 2033, 75 million people facing barriers to economic advancement will have quality jobs, and the mission of University of Phoenix is to provide access to higher education opportunities that enable students to develop the knowledge and skills necessary to achieve their professional goals, improve the performance of their organizations and provide leadership and service to their communities. 'Our work with JFF is about turning good intentions around learning and development into real, measurable progress, allowing us to build greater confidence in AI-generated recommendations and make transparent technology's role in promoting talent mobility,' shares Krishnaiah. 'Together, we can help employers unlock vital support services for creating holistic talent solutions and career pathways for the learners and workers we aim to serve.' The partnership highlights the University's collaboration with 2,000+ employers through its Adaptable Skills Solutions, offering customized workforce assessments in partnership with the University's technology affiliate Skillmore TM for a transformational combination with professional development and discounted education benefits. Skillmore TM is a trademark of Talent Mobility, Inc. Talent Mobility, Inc. (dba Skillmore) is an affiliate of University of Phoenix and requires a separate agreement for its services. The project will run through May 2026 and culminate in a field-facing impact report offering actionable insights for employers, educators, and technology developers. About University of Phoenix University of Phoenix innovates to help working adults enhance their careers and develop skills in a rapidly changing world. Flexible schedules, relevant courses, interactive learning, skills-mapped curriculum for our bachelor's and master's degree programs and a Career Services for Life® commitment help students more effectively pursue career and personal aspirations while balancing their busy lives. . JFF is building a future that works for everyone by transforming U.S. education and workforce systems to drive economic success for people, businesses, and communities. Learn more at
Business Wire
42 minutes ago
- Business Wire
Rosen Law Firm Encourages Hims & Hers Health, Inc. Investors to Inquire About Securities Class Action Investigation
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Hims & Hers Health, Inc. (NYSE: HIMS) resulting from allegations that Hims & Hers may have issued materially misleading business information to the investing public. So What: If you purchased Hims & Hers securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@ for information on the class action. What is this about: On June 23, 2025, before the market opened, Novo Nordisk issued a press release entitled 'Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing.' The press release further stated that, in late April, 'the FDA resolved the Wegovy ® shortage based on its conclusion that Novo Nordisk is fully meeting current and projected nationwide demand for this medicine. In support of transitioning patients from knock-off compounded versions to authentic, FDA-approved Wegovy ® through NovoCare ® Pharmacy, Novo Nordisk began collaborating with telehealth companies. Over one month into the collaboration, Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk.' On this news, Hims & Hers stock fell over 28% in intraday trading on June 23, 2025. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Attorney Advertising. Prior results do not guarantee a similar outcome.
Business Wire
43 minutes ago
- Business Wire
LifePlus Establishes Global Clinical Validation for First-of-Its-Kind Non-Invasive Glucose and Cuffless BP Monitoring Device and Platform
SAN JOSE, Calif.--(BUSINESS WIRE)-- LifePlus, a Silicon Valley startup redefining personal health monitoring, today announced the clinical validation of LifeLeaf ®, the world's first non-invasive and cuffless wearable for continuous glucose and blood pressure tracking. The device, tested in global multi-center trials including Mayo Clinic, AMCR Clinic – San Diego, CA, Cleveland Clinic – Abu Dhabi, and Hospital Sebarang Jaya – Penang, Malaysia, delivers real-time insights without needles, invasive sensors, or cuffs, setting a new standard in scalable, preventive care management. LifeLeaf delivers clinically validated performance without the usual barriers of needles, cuffs, or cost. Share 'LifeLeaf delivers clinically validated performance without the usual barriers of needles, cuffs, or cost,' said Dr. Samuel J. Asirvatham and Dr. Narayan G. Kowlgi of Cardiovascular Medicine, Mayo Clinic, Rochester, MN. 'By making blood pressure and glucose monitoring effortless and non-invasive, it drives better patient adherence, which is crucial for managing chronic conditions like hypertension and diabetes. This scalable solution has a strong potential to transform care models globally by enabling proactive, patient-friendly disease management.' Global Dataset LifePlus has collected and analyzed over 70,000 paired multi-biomarker datapoints from more than 500 human subjects across 14 countries and 4 continents. 'This robust dataset spans a wide range of demographics—including skin tone, age, gender, and BMI—supporting the development of proprietary signal processing and highly generalizable, multi-biomarker advanced AI/ML algorithms and models,' said Ben Mbouombouo, Chief Operating Officer and Product GM of LifePlus. Clinical Results LifePlus has already conducted multiple clinical studies to demonstrate clinical validation for LifeLeaf. The most recent results of its performance vs BGM for glucose monitoring are scheduled to be showcased at the upcoming American Diabetes Association (ADA) Meeting, June 20-23, 2025. Earlier, LifeLeaf's performance vs CGM was shared at the Advanced Technology and Treatment for Diabetes (ATTD) meeting in 2023. LifePlus also published clinical validation results for blood pressure in the European Society of Hypertension meeting in 2023. Please see key highlights below: Glucose Monitoring In head-to-head studies, LifeLeaf achieved an impressive 10.8% MARD against BGM references 1 and 8.5% MARD against Dexcom G6 2 for a target dynamic range of 70-250 mg/dL, demonstrating non-invasive glucose monitoring is not only possible, but viable and scalable for real-world use. LifeLeaf attained a low 2% outlier rate 1 in blinded continuous glucose monitoring studies, comparable with invasive alternatives and underscoring its clinical reliability. Blood Pressure The cuffless blood pressure feature of LifeLeaf demonstrated impressive accuracy, with a mean difference ± standard deviation of –0.02 ± 12.5 mmHg for systolic and 0.03± 8.4 mmHg for diastolic measurements 3 for a supported dynamic range of 90/55-170/110 mmHg, validated across multiple clinical studies and real-world settings. LifeLeaf collected indefinite long-term blood pressure data as opposed to traditional ambulatory monitors, offering continuous, real-world views. LifePlus is engaged with the world's leading clinicians to establish a new longitudinal metric for assessing arterial stiffness that may better predict long-term effects of hypertension and related cardiovascular outcomes. LifeLeaf is unique because it does not require needles, cuffs, or calibration as current solutions do. It is 70% more cost-effective over a 12-month period and supports effortless daily use, which is critical for maintaining a high degree of patient adherence and delivering preventive insights. 'The results presented at ADA this year show that LifeLeaf has the potential to provide accurate data, without invasiveness or complexity,' said Dr. Timothy S. Bailey of Headlands Research – AMCR Clinic, Escondido, CA, and Dr. Jerome S. Fischer of MDRequest, San Antonio, TX. 'This kind of non-invasive monitoring is uniquely poised to improve patient adherence and enable earlier detection – two critical factors in managing chronic conditions.' Upcoming Global Clinical Trials LifePlus is now initiating additional longitudinal outcome studies for LifeLeaf across Asia, Europe, Middle East and North America, focusing on prediabetic and hypertensive populations. The goal: to prove that continuous, passive monitoring can lead to earlier interventions and measurable reductions in chronic disease incidence. 'We're incredibly encouraged by the clinical validation at world-class institutions like Mayo Clinic and Cleveland Clinic,' said Dr. Alodeep Sanyal, co-founder and CEO of LifePlus. 'It confirms what we have believed from the beginning: that non-invasive, AI-powered monitoring can be reliable and scalable. The growing global interest from healthcare providers, partners and investors reaffirms that we are at the forefront of a major shift in how we manage and prevent chronic disease.' With global spending on diabetes and cardiovascular care projected to exceed $1.5 trillion annually by 2030, the market is primed for solutions that go beyond reactive treatment. LifeLeaf is the first clinically validated solution of its kind in this space, targeting a $100B+ total addressable market. To learn more about partnership, pilot opportunities, or investment in LifeLeaf's clinically validated platform, visit Footnotes 1. Improved accuracy of a fully non-invasive continuous glucose monitor in a diverse population. T. Bailey et al. American Diabetes Association (ADA) Annual Meeting 2025. 2. The feasibility of non-invasive continuous glucose monitoring with the novel LifeLeaf wristwatch and platform. T. Bailey et al. Advanced Technology and Treatment in Diabetes (ATTD) Annual Meeting 2023. 3. The feasibility of cuffless, non-occlusive blood pressure assessments using the novel LifeLeaf wristwatch and platform. European Society of Hypertension (ESH) Annual Meeting 2023. About LifePlus LifePlus is committed to transforming how people manage and improve their health. At the heart of our innovation is LifeLeaf ®, the world's first non-invasive, effortless, wrist-worn medical device and platform for continuous, real-time remote patient monitoring. Powered by AI, this technology empowers individuals with real-time insights into their vital health parameters, enabling proactive health management, early intervention, and seamless information sharing with loved ones and care teams. Designed for the billions worldwide at risk of chronic diseases, LifePlus is redefining everyday health monitoring with comfort, continuity, and confidence.
